81 results match your criteria infliximab multisystem


IVIG Compared to IVIG Plus Infliximab in Multisystem Inflammatory Syndrome in Children.

Pediatrics 2021 Sep 22. Epub 2021 Sep 22.

Department of Pediatrics, Section of Infectious Diseases, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO.

View Article and Full-Text PDF
September 2021

Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection in Children: One Year after the Onset of the Pandemic in a High-Incidence Area.

Viruses 2021 10 7;13(10). Epub 2021 Oct 7.

Department of Pediatrics, Istituto di Ricovero e Cura a Carattere Scientifico St. Orsola Polyclinic, University of Bologna, 40138 Bologna, Italy.

SARS-CoV-2 infection in children can trigger cardiovascular manifestations potentially requiring an intensive treatment and defining a new entity named Multisystem Inflammatory Syndrome in Children (MIS-C), whose features partially overlap with Kawasaki Disease (KD). A cross-sectional study including all diagnoses of MIS-C and KD from April 2020 to May 2021 in our metropolitan area was conducted evaluating clinical, laboratory (including immunological response, cytokines, and markers of myocardial damage), and cardiac (coronary and non-coronary) features at onset of the diseases. Evolution of ventricular dysfunction, valve regurgitations, and coronary lesions was documented. Read More

View Article and Full-Text PDF
October 2021

IVIG Compared to IVIG Plus Infliximab in Multisystem Inflammatory Syndrome in Children.

Pediatrics 2021 Sep 21. Epub 2021 Sep 21.

Department of Pediatrics, Section of Infectious Diseases, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO;

View Article and Full-Text PDF
September 2021

Longitudinally extensive transverse myelitis as a sign of multisystem inflammatory syndrome following COVID-19 infection: A pediatric case report.

J Neuroimmunol 2021 11 28;360:577704. Epub 2021 Aug 28.

Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

COVID-19 infection can cause inflammatory reactions that could involve several organs. In the pediatric population, Multi-System Inflammatory Syndrome in Children (MIS-C) has been reported as one of the consequences of COVID-19. We report a unique pediatric COVID-19 patient with MIS-C, associated with paralysis of the extremities. Read More

View Article and Full-Text PDF
November 2021

Infliximab: A treatment option for multisystem inflammatory syndrome in children with ulcerative colitis?

Turk Arch Pediatr 2021 1;56(3):267-269. Epub 2021 May 1.

Department of Pediatric Gastroenterology and Hepatology, Selcuk University School of Medicine, Konya, Turkey.

View Article and Full-Text PDF

Cryopyrin-associated periodic syndrome with inflammatory bowel disease: A case study.

JGH Open 2021 May 9;5(5):629-631. Epub 2021 Mar 9.

Faculty of Health and Medical Sciences, The University of Adelaide Adelaide South Australia Australia.

Cryopyrin-associated Periodic Syndrome (CAPS) is a rare, genetic autoinflammatory condition associated with NLRP3 gene mutations, causing upregulated innate immunity. CAPS manifests as systemic inflammation, causing a constellation of symptoms on a clinical spectrum of phenotypical severity: Familial Cold Autoinflammatory Syndrome being the mildest, Muckle-Wells Syndrome moderate, and Neonatal Onset Multisystem Inflammatory Disease the most severe, with phenotype spectrum overlap. The treatment in Australia for CAPS is interleukin-1 blockade with receptor antagonist, anakinra. Read More

View Article and Full-Text PDF

Diversity of Cardiac and Gastrointestinal Presentations of Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Case Series.

Glob Pediatr Health 2021 22;8:2333794X21996613. Epub 2021 Feb 22.

Beaumont Children's Hospital, Royal Oak, MI, USA.

COVID-19 is generally a benign or asymptomatic infection in children, but can occasionally be severe or fatal. Delayed presentation of COVID-19 with hyperinflammation and multi-organ involvement was recently recognized, designated the Multisystem Inflammatory Syndrome in Children (MIS-C). Six children with MIS-C with molecular and serologic evidence of SARS-CoV-2 infection were admitted to our hospital between May 5, 2020 and June 25, 2020. Read More

View Article and Full-Text PDF
February 2021

A fine line between macrophage activation syndrome and multisystem inflammatory syndrome in children - literature review based on two case reports.

Reumatologia 2021 28;59(1):47-57. Epub 2021 Feb 28.

Pediatric Center Maria Konopnicka, Central Clinical Hospital of the Medical University of Lodz, Poland.

Multisystem inflammatory syndrome in children is a newly described condition temporarily associated with severe acute respiratory syndrome coronavirus 2. The primary observations indicated coronavirus disease 2019 infection in children to be mild. However, recent reports have revealed a correlation between multisystem inflammatory symptoms and coronavirus infection. Read More

View Article and Full-Text PDF
February 2021

COVID-19-Associated Multisystem Inflammatory Syndrome Complicated with Giant Coronary Artery Aneurysm.

Case Rep Pediatr 2021 6;2021:8836403. Epub 2021 Jan 6.

Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.

In the early stages of the outbreak of the novel coronavirus disease 2019 (COVID-19), it was assumed that this infection is very mild and uncommon in children. However, recent reports have shown that children may also develop the disease and its severe complications. These complications included shock, multisystem inflammatory syndrome in children (MIS-C), and pneumonia in children. Read More

View Article and Full-Text PDF
January 2021

SARS-CoV-2-associated multisystem inflammatory syndrome in children: clinical manifestations and the role of infliximab treatment.

Eur J Pediatr 2021 May 16;180(5):1581-1591. Epub 2021 Jan 16.

Division of Infectious Diseases, Children's Hospital of Michigan, 3901 Beaubien Blvd, Detroit, MI, 48201, USA.

This study was conducted to assess the clinical spectrum, management, and outcome of SARS-CoV-2-related multisystem inflammatory syndrome in children (MIS-C). We reviewed medical records of children with MIS-C diagnosis seen at the Children's Hospital of Michigan in Detroit between April and June 2020. Thirty-three children were identified including 22 who required critical care (group 1) and 11 with less intense inflammation (group 2). Read More

View Article and Full-Text PDF

Clinical features, diagnosis, and outcomes of multisystem inflammatory syndrome in children associated with coronavirus disease 2019.

Clin Exp Pediatr 2021 Feb 30;64(2):68-75. Epub 2020 Dec 30.

Department of Pediatrics, Bundang Jesaeng Hospital, Daejin Medical Center, Seongnam, Korea.

The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been spreading worldwide since December 2019. Hundreds of cases of children and adolescents with Kawasaki disease (KD)-like hyperinflammatory illness have been reported in Europe and the United States during the peak of the COVID-19 pandemic with or without shock and cardiac dysfunction. These patients tested positive for the polymerase chain reaction or antibody test for SARS-CoV-2 or had a history of recent exposure to COVID-19. Read More

View Article and Full-Text PDF
February 2021

Inflammatory Bowel Disease Presenting With Concurrent COVID-19 Multisystem Inflammatory Syndrome.

Pediatrics 2021 04 7;147(4). Epub 2021 Jan 7.

Division of Gastroenterology, Hepatology and Nutrition and

Coronavirus disease 2019 is associated with a postinfectious multisystem inflammatory syndrome in children (MIS-C). This syndrome is marked by cytokine storm and multiorgan dysfunction, often affecting the gastrointestinal tract, the heart, and the hematopoietic system. We describe the case of a 16-year-old boy with an initial presentation of severe inflammatory bowel disease and concurrent MIS-C. Read More

View Article and Full-Text PDF

Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist.

Rheumatology (Oxford) 2021 02;60(2):911-917

Department of Paediatric Rheumatology, London, UK.

Objectives: The objectives of this study were (i) to describe the clinical presentation, treatment and outcome of paediatric inflammatory multisystem syndrome temporally related to Sars-CoV-2 (PIMS-TS) in children; (ii) to propose a framework to guide multidisciplinary team (MDT) management; and (iii) to highlight the role of the paediatric rheumatologist in this context.

Methods: This study involved a retrospective case notes review of patients referred to a single specialist paediatric centre with suspected PIMS-TS, with a focus on clinical presentation, laboratory parameters, treatment, and outcome in the context of an MDT framework.

Results: Nineteen children of median age 9. Read More

View Article and Full-Text PDF
February 2021

Bilateral Retrobulbar Optic Neuritis as the First Manifestation of Neuro-Behçet Disease.

Case Rep Rheumatol 2020 6;2020:8834399. Epub 2020 Oct 6.

Department of Pediatric, Imam Hossein Children's Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.

Background: Behçet disease (BD) is a polygenic and chronic autoinflammatory multisystem vasculitis. Acute optic neuritis has been rarely reported in patients with BD, especially in children. . Read More

View Article and Full-Text PDF
October 2020

Paediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 [PIMS-TS] in a Patient Receiving Infliximab Therapy for Inflammatory Bowel Disease.

J Crohns Colitis 2021 Apr;15(4):687-691

Department of Paediatric Gastroenterology and Nutrition, Royal Hospital for Sick Children, Edinburgh, Uk.

Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 [PIMS-TS] is a newly described condition. It has a spectrum of presentations proposed to occur as part of a post-infectious immune response. We report the first case of PIMS-TS in a child on established anti-tumour necrosis factor alpha [anti-TNFα] therapy; a 10 year-old girl with ulcerative colitis treated with infliximab. Read More

View Article and Full-Text PDF

A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process.

Lancet Child Adolesc Health 2021 02 18;5(2):133-141. Epub 2020 Sep 18.

Department of Paediatric Surgery, Alder Hey Children's Hospital, Liverpool, UK; School of Life Sciences, University of Liverpool, Liverpool, UK; NHS England/Improvement, Redditch, UK.

Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS) is a novel condition that was first reported in April, 2020. We aimed to develop a national consensus management pathway for the UK to provide guidance for clinicians caring for children with PIMS-TS. A three-phase online Delphi process and virtual consensus meeting sought consensus over the investigation, management, and research priorities from multidisciplinary clinicians caring for children with PIMS-TS. Read More

View Article and Full-Text PDF
February 2021

Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation.

Paediatr Respir Rev 2021 Jun 11;38:51-57. Epub 2020 Aug 11.

Department of Paediatric Respiratory Medicine, King's College Hospital, London, United Kingdom; Institute for Women's and Children's Health, King's College London, London, United Kingdom. Electronic address:

Multisystem Inflammatory Syndrome in Children (MIS-C) is a new phenomenon reported worldwide with temporal association with Covid-19. The objective of this paper is to evaluate reported cases in children and adolescents. From 1726 papers, 35 documented papers related to MIS-C cases identified 783 individual cases of MIS-C between March-June 2020; with 55% being male (n = 435) and a median age of 8. Read More

View Article and Full-Text PDF

Sarcoidosis and the Nervous System.

Continuum (Minneap Minn) 2020 06;26(3):695-715

Purpose Of Review: This article provides an overview and update on the neurologic manifestations of sarcoidosis.

Recent Findings: The 2018 Neurosarcoidosis Consortium diagnostic criteria emphasize that biopsy is key for diagnosis and determines the level of diagnostic certainty. Thus, definite neurosarcoidosis requires nervous system biopsy and probable neurosarcoidosis requires biopsy from extraneural tissue. Read More

View Article and Full-Text PDF

Pediatric Crohn Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated With Infliximab.

J Pediatr Gastroenterol Nutr 2020 08;71(2):153-155

Department of Pediatric Gastroenterology, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai, New York, NY.

Coronavirus disease 2019 (COVID-19) may lead to a severe inflammatory response referred to as a cytokine storm. We describe a case of severe COVID-19 infection in a recently diagnosed pediatric Crohn disease patient successfully treated with tumor necrosis factor-alpha (TNF-α) blockade. The patient presented with 5 days of fever, an erythematous maculopapular facial rash, and abdominal pain without respiratory symptoms. Read More

View Article and Full-Text PDF

Limited auricular relapsing polychondritis in a child treated successfully with infliximab.

BMJ Case Rep 2019 May 23;12(5). Epub 2019 May 23.

Department of Paediatrics, King Abdulaziz Medical City and King Saud Bin Abdulaziz University for Health Sciences - Ministry of National Guard, Riyadh, Saudi Arabia.

Relapsing polychondritis (RP) is a rare progressive and destructive multisystem disorder characterised by recurrent inflammation of cartilaginous structures. It is a rare disease in paediatrics compared with adults. In children, the diagnosis is either delayed or overlooked due to low incidence. Read More

View Article and Full-Text PDF

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.

J Am Acad Dermatol 2019 Apr 13;80(4):1029-1072. Epub 2019 Feb 13.

Dermatology Research and Education Foundation, Irvine, California.

Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations based on the available evidence. Read More

View Article and Full-Text PDF

Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety.

Semin Arthritis Rheum 2019 06 16;48(6):1093-1104. Epub 2018 Oct 16.

Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. Electronic address:

Background: Though anti-tumor necrosis factor agents (anti-TNFs) have been recommended as third-line therapy for sarcoidosis, an up-to-date systematic synthesis of their efficacy and safety is lacking.

Objectives: To systematically review the literature to characterize the efficacy and safety of anti-TNFs in sarcoidosis.

Settings: All countries and treatment settings were included. Read More

View Article and Full-Text PDF

Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.

J Emerg Med 2018 10 16;55(4):489-502. Epub 2018 Aug 16.

Department of Emergency Medicine, University of California San Diego School of Medicine, San Diego, California.

Background: Immune checkpoint inhibitors (ICIs) are a novel class of drugs used in cancer immunotherapy that are becoming more commonly used among advanced-stage cancers. Unfortunately, these therapies are sometimes associated with often subtle, potentially fatal immune-related adverse events (irAEs).

Objectives: We conducted a review of relevant primary research and clinical guidelines in oncology, pharmacology, and other literature, and synthesized this information to address the needs of the emergency physician in the acute management of irAEs. Read More

View Article and Full-Text PDF
October 2018

Kawasaki disease shock syndrome: Unique and severe subtype of Kawasaki disease.

Pediatr Int 2018 Sep;60(9):781-790

Clinical Immunology Department, National Institute of Pediatrics, Médica Sur Hospital, Mexico City, Mexico.

Background: Kawasaki disease shock syndrome (KDSS) is an uncommon presentation of Kawasaki disease (KD). KDSS has been associated with more severe markers of inflammation, coronary abnormalities and i.v. Read More

View Article and Full-Text PDF
September 2018

Neurosarcoidosis associated with intracerebral haemorrhage: a challenge in diagnosis and management.

Pract Neurol 2018 Jun 23;18(3):246-249. Epub 2018 Jan 23.

Department of Neurology, Salford Royal NHS Foundation Trust, Salford, UK.

Sarcoidosis is an idiopathic multisystem granulomatous disorder of unknown cause. Nervous system involvement (central and/or peripheral) is uncommon, developing in 5%-10%. The presenting symptoms are variable, reflecting the level of involvement, and frequently fluctuate and progress. Read More

View Article and Full-Text PDF

Sarcoidosis with ankylosing spondylitis: changing therapeutic landscape.

Sarcoidosis Vasc Diffuse Lung Dis 2018 28;35(3):285-288. Epub 2018 Apr 28.

Metro Centre for Respiratory Diseases, Metro Multispecialty Hospital, Noida, UP, India.

Sarcoidosis is an inflammatory multisystem disease which rarely may coexist in patients with other autoimmune disease like ankylosing spondylitis (AS). The presence of such as association causes diagnostic and management dilemmas as sarcoidosis has been reported to develop in patients of AS treated with tumour necrosis factor alpha (TNF-α) inhibitors. We describe a 49-year-old male with ankylosing spondylitis and histologically proven sarcoidosis who was treated with infliximab and improved. Read More

View Article and Full-Text PDF

High-Cost Sarcoidosis Patients in the United States: Patient Characteristics and Patterns of Health Care Resource Utilization.

J Manag Care Spec Pharm 2017 Dec 17;23(12):1261-1269. Epub 2017 Oct 17.

2 Mallinckrodt Pharmaceuticals, Hampton, New Jersey.

Background: Sarcoidosis is a multisystem inflammatory disorder characterized by the presence of noncaseating granulomas in involved organs. Prior research has found that sarcoidosis imposes a significant economic burden to U.S. Read More

View Article and Full-Text PDF
December 2017

Relapsing polychondritis, an underestimated dermatological urgency: case report and literature review.

Int J Dermatol 2017 Dec 9;56(12):1379-1386. Epub 2017 Oct 9.

Dermatology Service, Samaritana University Hospital - ESE, Bogotá, Colombia.

Background: Relapsing polychondritis is an autoimmune multisystemic disease with primary chondral involvement. Its high mortality and morbidity make it a real clinical challenge.

Case Description: A 32-year-old woman with a history of relapsing polychondritis, refractory to multiple treatments, with multisystem compromise, imminent risk of death due to severe tracheobronchial damage and difficult ventilatory support, and successful treatment with infliximab. Read More

View Article and Full-Text PDF
December 2017

Erdheim-Chester disease (ECD): Case report, clinical and basic investigations, and review of literature.

Medicine (Baltimore) 2016 Oct;95(42):e5167

Baruch Padeh Medical Center, Poriya, Faculty of Medicine in the Galilee - Bar Ilan University, Israel Senior Physician Specialists in Family Medicine, Department of Family Medicine and Faculty of Medicine in the Galilee - Bar Ilan University, Israel Professor of Clinical Neuroscience, Neuropsychopharmacology & Population Genetics; Department of clinical Neuroscience - EMMS Nazareth Hospital, Nazareth, Israel.

Background: Erdheim-Chester disease (ECD) is an uncommon aggressive, multisystem form of non-Langerhans' cell histocytosis, which was firstly reported by Jakob Erdheim and William chester in 1930. The disease pathological features encompass an aberrant multiplication, overproduction and accumulation of white blood cells called histiocytes within multiple tissues and organs. Herein, we present a case of ECD owing to the rarity of this disease (roughly 550 cases have been described in the literature to date). Read More

View Article and Full-Text PDF
October 2016

Pediatric gastrointestinal sarcoidosis: Successful treatment with infliximab.

Saudi J Gastroenterol 2016 Sep-Oct;22(5):391-395

Department of Pediatrics, Children's Specialized Hospital, King Fahad Medical City, Riyadh, Saudi Arabia.

Gastrointestinal sarcoidosis is a rare disease with very limited data in children. Here we report the first pediatric case of successful treatment with infliximab. The first case was an 8-year-old Saudi girl who presented with fever, weight loss, and abdominal pain that was followed in a few months with hematemesis and development of hepatosplenomegaly. Read More

View Article and Full-Text PDF